OLFM4 / GW112 Antibody

OLFM4 / GW112 Antibody Datasheet

OLFM4 / GW112 Antibody Product Information

• Immunogen: Recombinant Human OLFM4 / GW112 protein (Catalog#11639-H08H)
• Antibody Type: Mouse Monoclonal Antibody ( Mouse mAb Service Platform )
• Clone ID: 02
• Ig Type: Mouse IgG1
• Formulation: 0.2 μm filtered solution in PBS with 5% trehalose
• Preparation: This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human OLFM4 / GW112 (rh OLFM4 / GW112; Catalog#11639-H08H; NP_006409.3; Met 1-Gln 510). The IgG fraction of the cell culture supernatant was purified by Protein A affinity chromatography.

OLFM4 / GW112 Antibody Usage Guide

• Specificity: Human OLFM4 / GW112
• No cross-reactivity in ELISA with

  Human cell lysate (293 cell line)

• Direct ELISA: This antibody can be used at 0.5-1 μg/mL with the appropriate secondary reagents to detect Human OLFM4. The detection limit for Human OLFM4 is approximately 0.078 ng/well.
• Storage: This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -70℃. Preservative-Free.
  Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles.

OLFM4 / GW112 Antibody Background

Olfactomedin-4, also known as G-CSF-stimulated clone 1 protein, Antiapoptotic protein GW112, and OLFM4, is a secreted protein which contains oneolfactomedin-like domain. OLFM4 is expressed during myeloid lineage development. It is strongly expressed in the prostate, small intestine and colon and moderately expressed in the bone marrow and stomach. OLFM4 is highly expressed in pancreatic cancer tissues and shows an elevated expression level during the early S phase of the cell cycle. It is also expressed at high levels in stomach cancer and colon cancer tissues. Inhibition of ROS or the ERK pathway remarkably decreased G-CSF-induced OLFM4 expression. OLFM4 is an antiapoptotic factor that promotes tumor growth. OLFM4 promotes proliferation of pancreatic cancer cells by favoring the transition from the S to G2/M phase. OLFM4 also facilitates cell adhesion. Induction of OLFM4 in cancer cells was reported to have a novel antiapoptotic action via binding to the potent apoptosis inducer GRIM-19. The human OLFM4 is also thought to be a useful marker for early myeloid development.

References

1. Zhang J., et al., 2002, Gene 283: 83-93.
2. Zhang X., et al., 2004, Cancer Res. 64: 2474-2481.
3. Kobayashi D., 2007, et al., Cancer Sci. 98: 334-340.
4. Kobayashi, D.et al., 2007, Cancer Sci. 98 (3): 334-40.
5. Van der Flier, L.G. et al., 2009, Gastroenterology. 137 (1): 15-7.